CDK4/6 inhibitor–based regimens represent the standard of care in the first-line treatment of women with ER-positive, ...

Hurvitz concludes that these results validate the PAM pathway as a key molecular driver in HR+/HER2– advanced breast cancer ...

CYP2D6 poor metabolizers had ~5-fold higher payload exposure and excess grade ≥3 mucositis, neutropenia, febrile neutropenia, ...

Amended IND clearance adds updated CMC elements (manufacturers, formulation, storage) and permits US enrollment for THIO-101 ...

Dr McDonald shares promising data linking GLP-1 use to lower breast cancer risk, highlighting the need for clinical trials to ...

FDA fast-tracks VS-7375, an oral KRAS G12D inhibitor, opening new hope for pretreated advanced NSCLC and fueling pivotal ...

Natco Pharma and Lupin gained FDA approval for bioequivalent generic eribulin mesylate injection, potentially reducing ...

ASCO 2026 data link chronic-stress allostatic load to higher early-onset cancer risk, suggesting new tools for screening ...

A novel treatment approach combining triple-oral metronomic chemotherapy with ultra-low-dose immunotherapy (nivolumab; TMC-I ...

Abemaciclib (Verzenio) reduced the risk of progression or death by 62% compared with placebo in patients with advanced ...

ASCO 2026: PSMAddition shows 177Lu-PSMA-617 boosts rPFS across mHSPC subgroups, with steady safety and insights on PSMA PET ...

Iza-bren is a potentially first-in-class bispecific ADC designed to target both EGFR and HER3. It features high affinity for ...